Life sciences and diagnostics company Danaher (NYSE: DHR) is one of the very few companies that has benefited from the COVID-19 pandemic. Its diagnostic tests detect the virus, and its life sciences tools help customers research and develop vaccines and therapies. As such, Danaher will have another solid year in 2021 -- but what lies beyond the pandemic? Here's what you need to know before buying the stock.
Image source: Getty Images.
The tale of Danaher's past year is in the chart below. After the pandemic spread out of China, the company took an initial hit in the second quarter, only to recover strongly as life sciences and diagnostics revenue soared through 2020 and into 2021. Meanwhile, core sales in the environmental and applied solutions segment (a collection of water treatment, inkjet printing, and color management solutions) showed positive growth again with the improving economy.
Source Fool.com